GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (OTCPK:CALA) » Definitions » Forward Rate of Return (Yacktman) %

Calithera Biosciences (Calithera Biosciences) Forward Rate of Return (Yacktman) % : 0.00% (As of Dec. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Calithera Biosciences's forward rate of return for was 0.00%.

The historical rank and industry rank for Calithera Biosciences's Forward Rate of Return (Yacktman) % or its related term are showing as below:

CALA's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 10.72
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Calithera Biosciences Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Calithera Biosciences's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences Forward Rate of Return (Yacktman) % Chart

Calithera Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Calithera Biosciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Calithera Biosciences's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Calithera Biosciences's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calithera Biosciences's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calithera Biosciences's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Calithera Biosciences's Forward Rate of Return (Yacktman) % falls into.



Calithera Biosciences Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Calithera Biosciences's Forward Rate of Return of Dec. 2022 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/3.26+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calithera Biosciences  (OTCPK:CALA) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Calithera Biosciences Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Calithera Biosciences (Calithera Biosciences) Business Description

Industry
Traded in Other Exchanges
N/A
Address
343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
Executives
Deepika Pakianathan director, 10 percent owner 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Takeda Ventures, Inc. 10 percent owner 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Keith Orford officer: SR. VP, CLINICAL DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jonathan G Drachman director 21823 30TH DRIVE SE, BOTHELL WA 98021
Susan Molineaux director, officer: PRESIDENT AND CEO C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Christopher Molineaux officer: SR. VP, DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Emil Kuriakose officer: CHIEF MEDICAL OFFICER 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Millennium Pharmaceuticals Inc 10 percent owner 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Stephanie Wong officer: VP, FINANCE 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Calithera Biosciences (Calithera Biosciences) Headlines

From GuruFocus

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

By Stock market mentor Stock market mentor 01-09-2023

Calithera Biosciences Announces 1-for-20 Reverse Stock Split

By GuruFocusNews GuruFocusNews 07-04-2022